ישראל - עברית - Ministry of Health

unipharm ltd, israel - simvastatin - טבליות מצופות פילם - simvastatin 40 mg - simvastatin

ישראל - עברית - Ministry of Health

unipharm ltd, israel - simvastatin - טבליות מצופות פילם - simvastatin 80 mg - simvastatin

ישראל - עברית - Ministry of Health

bioavenir ltd - pravastatin sodium 40 mg - tablets - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin

ישראל - עברית - Ministry of Health

unipharm ltd, israel - simvastatin - טבליות מצופות פילם - simvastatin 10 mg - simvastatin

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - simvastatin - קפליות - simvastatin 80 mg - simvastatin

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe 10 mg; simvastatin 10 mg - tablets - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ישראל - עברית - Ministry of Health

novartis pharma services ag - fluvastatin as sodium 20 mg - capsules - fluvastatin - reduction of elevated levels of total cholesterol, ldl cholesterol, apolipoprotein b and triglycerides and increase of hdl cholesterol in patients with primary hypercholesterolemia and primary mixed dyslipidemia (fredrickson types iia and iib) in whom dietary measures have proved insufficiently effective.

ישראל - עברית - Ministry of Health

novartis pharma services ag - fluvastatin as sodium 40 mg - capsules - fluvastatin - reduction of elevated levels of total cholesterol, ldl cholesterol, apolipoprotein b and triglycerides and increase of hdl cholesterol in patients with primary hypercholesterolemia and primary mixed dyslipidemia (fredrickson types iia and iib) in whom dietary measures have proved insufficiently effective.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - simvastatin 40 mg - tablets - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simovil is indicated to: reduce the risk of total mortality by reducing coronary death; reduce the risk of non-fatal myocardial infarction; reduce the risk for undergoing myocardial revascularization procedures; reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simovil is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simovil therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simovil is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglycerid